These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38617129)

  • 1. Potential Effects on Elderly People From Nirsevimab Use in Infants.
    Sanz-Muñoz I; Castrodeza-Sanz J; Eiros JM
    Open Respir Arch; 2024; 6(2):100320. PubMed ID: 38617129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
    Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
    Front Immunol; 2021; 12():708939. PubMed ID: 34456918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
    Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
    N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Wilkins D; Langedijk AC; Lebbink RJ; Morehouse C; Abram ME; Ahani B; Aksyuk AA; Baraldi E; Brady T; Chen AT; Chi H; Choi EH; Cohen R; Danilenko DM; Gopalakrishnan V; Greenough A; Heikkinen T; Hosoya M; Keller C; Kelly EJ; Kragten-Tabatabaie L; Martinón-Torres F; de Los Santos AHM; Nunes MC; Palomino MA; Papenburg J; Pernica JM; Richmond P; Stein RT; Tuffy KM; Verwey C; Esser MT; Tabor DE; Bont LJ;
    Lancet Infect Dis; 2023 Jul; 23(7):856-866. PubMed ID: 36940703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
    Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT
    Nat Med; 2023 May; 29(5):1172-1179. PubMed ID: 37095249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children.
    Fly JH; Eiland LS; Stultz JS
    Ann Pharmacother; 2024 Apr; ():10600280241243357. PubMed ID: 38654469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model.
    Voirin N; Virlogeux V; Demont C; Kieffer A
    Infect Dis Ther; 2022 Feb; 11(1):277-292. PubMed ID: 34813073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.